KR20160066736A - COMPOSITION FOR MOISTURIZING THE SKIN CONTAINING (2S)-1-O-LINOLEOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL - Google Patents

Abstract

The present invention relates to a composition for moisturizing the skin and, more specifically, to a composition which has excellent effects of recovering damaged skin barrier function and increasing skin moisturizing power by containing (2S)-1-O-linoleoyl-3-O-β-D-galactopyranosyl-sn-glycerol as an active ingredient.

Description

(2S) -1-O-linoleoyl-3-O-beta-D-galactopyranosyl-sn-glycerol -3-O- [beta] -D-galactopyranosyl-sn-glycerol}

The present invention relates to a composition for moisturizing, and more particularly to a composition for moisturizing, which contains (2S) -1-O-linoleoyl-3-0-? -D-galactopyranosyl- The present invention relates to a composition having an excellent effect of restoring a barrier function and increasing skin moisturizing ability.

Skin plays a very important role as a barrier function to protect individuals from the outside. The barrier function is a protection function for protecting against various stimuli (chemicals, air pollutants, dry environment, ultraviolet rays, etc.) from the outside and excessive divergence of water in the body through the skin. Such protection function is a function of protecting the stratum corneum The function can be maintained only when it is normally formed.

The outermost stratum corneum (horney layer) of the epidermis is formed from keratinocytes, and consists of keratinocytes with complete differentiation and a surrounding lipid layer (Marcelo CL et al . , J. Invest . Dermatol . 80 , pp 37-44, 1983).

The keratinocyte is a characteristic cell in which basal cells continuously proliferating in the lowest epidermis undergo a stepwise change in morphology and function and are elevated to the surface of the skin. After a certain period of time, And the new keratinocyte replaces its function. This repetitive sequence of changes is called "epidermal cell differentiation" or "keratinization".

In addition, during keratinization, keratinocytes form natural moisturizing factors (NMF) and intercellular lipids (ceramides, cholesterol, fatty acids) and form stratum corneum, which gives firmness and flexibility to the stratum corneum, barrier function.

Such stratum corneum can easily lose its function due to environmental factors such as excessive washing, bathing and other lifestyle factors, dry air pollutants, and endogenous diseases such as atopic skin and senile skin. In fact, Due to the increasing number of factors, dry skin symptoms and their complaints have been increasing recently.

Therefore, in order to maintain proper skin moisture, various studies have been made to supply water from the outside or to prevent water loss from the body. Various moisturizers having moisture retention ability have been developed. As a skin moisturizing agent, it is common to use a substance capable of increasing water retention in the stratum corneum such as ceramide and essential fatty acid and lipid complex (Rawlings AV et al . , J. Invest . Dermatol. , 5, pp731- 741, 1994).

However, recently, the risk factors for skin are increasing, and changes in dietary patterns slow down the generation and decline of the stratum corneum, and the function of the keratinocyte is reduced, so that the amount of the moisturizing factor and lipid in the stratum corneum is decreased, There is an increasing trend in people with skin that can not function as a skin barrier. Such breakdown of the skin barrier function causes various skin diseases such as dry skin, atopic dermatitis, contact dermatitis and psoriasis. Such diseases can be expected to be alleviated by moisturizing agents having a conventional moisture retention function but it is difficult to achieve fundamental healing.

On the other hand, (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol has been known to have anticancer and anti-inflammatory effects (Cha BJ et al., Glycosyl glycerides from hydrophobic Panax ginseng inhibited NO production in LPS-stimulated RAW264.7 cells, Journal of Ginseng Research (2014), doi: 10.1016 / j.jgr.2014.10.005), the efficacy of the above compounds in relation to the improvement of skin condition is not yet known in detail.

Korean Patent Laid-Open No. 10-2012-0083943 (published on July 27, 2012)

Cha BJ et al., Glycosyl glycerides from hydrophobic Panax ginseng inhibited NO production in LPS-stimulated RAW 264.7 cells, Journal of Ginseng Research (2014), doi: 10.1016 / j.jr.2014.10.005

Therefore, the inventors of the present invention have been studying for a substance showing excellent skin moisturizing effect and found that (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl- And the effect of increasing the amount of moisturizing the skin is excellent. Thus, the present invention has been completed.

Accordingly, an object of the present invention is to provide a composition containing (2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol as an active ingredient to improve skin moisturizing effect and damaged skin barrier By weight of the composition.

(2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol, which is a compound represented by the following general formula (1) By weight of the composition.

The composition of the present invention not only exhibits an effect of restoring damaged skin barrier function and increasing skin moisturizing power, but also exhibits excellent skin regeneration effect. Therefore, a composition containing (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol can be used for skin moisturizing, for strengthening skin barrier function, As the composition for induction, it can be usefully used for preventing or improving dry skin, atopic dermatitis, contact dermatitis, psoriasis and the like.

The composition according to the present invention is a composition comprising (2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol ((2S) -1-0-linoleoyl- -D-galactopyranosyl-sn-glycerol) as an active ingredient to improve the skin moisturizing ability.

The (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol used in the present invention has a structure represented by the following formula (1).

[Chemical Formula 1]

The (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol used in the present invention is a glycosyl glyceride-based [Cha BJ et al., Glycosyl glycerides from hydrophobic Panax ginseng inhibited NO production in LPS-stimulated RAW264.7 cells, Journal of Ginseng Research (2014), doi: 10.1016 / j.jgr.2014.10.005], but the present invention is not limited thereto. May be extracted from plants, synthesized according to methods known in the art, and commercially available ones may be used.

The composition according to the present invention is used in an amount of from 0.001 to 50% by weight, preferably from 0.01 to 50% by weight, based on the total weight of the composition, of (2S) -1-O-linoleoyl-3-0-? -D- galactopyranosyl- To 30% by weight, and more preferably from 0.1% to 10% by weight. When the content of (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol is less than 0.001% by weight, %, There is a problem of skin safety or shape.

The composition for moisturizing according to the present invention can be used for enhancing skin barrier function and inducing differentiation of dermal keratinocyte. Therefore, the composition for preventing or improving skin dryness, atopic dermatitis, contact dermatitis or psoriasis caused by incompleteness of epidermal differentiation Can be usefully used as an external composition for skin.

Also, the composition according to the present invention is excellent in the ability to recover damaged skin barrier and increase skin moisture content, and can be used as a composition for skin regeneration.

The composition of the present invention may be formulated as an external preparation for skin, in particular as a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base. In addition, the composition of the present invention may be provided in any form suitable for topical application, for example, as a solution, an emulsion obtained by dispersing an oil phase in water phase, an emulsion obtained by dispersing water phase in water phase, a suspension, a solid, a gel, Pastes, foams, or aerosol compositions. Specifically, the composition of the present invention may be provided in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a cone stick. Compositions of such formulations may be prepared according to conventional methods in the art.

In particular, the composition for external application for skin of the present invention is not particularly limited as a composition for hair or scalp. For example, hair tonic, hair nutritional lotion, scalp treatment, hair treatment, hair shampoo, hair rinse, Scalp hair combined treatment, and the like.

In addition, the composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, to the extent that the main effect is not impaired. The composition according to the present invention may further comprise a humectant, an emollient, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic or inorganic pigment, a perfume, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by a person skilled in the art within the range not impairing the object and effect of the present invention, and the amount thereof may be from 0.01 to 5% by weight, specifically from 0.01 to 3% by weight based on the total weight of the composition .

In addition, the composition of the present invention can be formulated as a pharmaceutical composition. When the composition according to the present invention is applied to medicines, it may be formulated into oral, parenteral or parenteral dosage forms in solid, semi-solid or liquid form by adding an inorganic or organic carrier compatible with the active ingredient used in the present invention , The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.

Examples of the formulations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. In addition, the formulations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to the present invention can be easily formulated into an active ingredient by carrying out the composition according to a conventional method. In this case, a surfactant, excipient, coloring agent, spice, preservative, stabilizer, buffer, suspending agent, have.

The dosage of the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, body weight, pathological condition and severity of the subject to be treated, route of administration, or judgment of the prescriber. Determination of the appropriate dose based on these factors is well within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

Referential Example 1 Preparation of (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol

(2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol for the purpose of testing the efficacy of the composition of the present invention has been described in the prior art (Cha BJ et al., Glycosyl glycerides from hydrophobic Panax ginseng inhibited NO production in LPS-stimulated RAW264.7 cells, Journal of Ginseng Research (2014), doi: 10.1016 / j.jgr.2014.10.005).

[Test Example 1] Measurement of promoting effect of keratinocyte differentiation

(2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol To examine the effect of promoting the differentiation of cells, differentiation of keratinocytes The amount of CE (Cornified Envelope) produced was measured by absorbance.

First, the keratinocytes (HEK; Lonza, NHEK-Neonatal Normal Human Epidermal Keratinocytes, Pooled) isolated from the epidermis of the neonate were placed in a culture flask and adhered to the bottom. After treating the (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol of Reference Example 1 at a concentration of 5 ppm, the cells reached 70 to 80% The cells were cultured for 5 days until they were grown. At this time, low calcium (0.03 mM) and high calcium (1.2 mM) treatment groups were negative control and positive control, respectively. Then, the cultured cells were harvested, washed with PBS (Phosphate buffered saline), and then suspended in 10 mM Tris-HCl buffer (Tris-HCl, pH 7.4) containing 2% SDS (sodium dodecyl sulfate) and 20 mM DTT (Dithiothreitol) pH 7.4) was added, sonication, boiling, and centrifugation. The precipitate was suspended again in 1 ml of PBS and the absorbance at 340 nm was measured. Separately, a part of the solution after the sonication was taken to measure the protein content and used as a standard in evaluating the degree of cell differentiation. The results are shown in Table 1 below.

Test substance The ability to differentiate in keratinocytes (%) Low calcium (0.03 mM) solution
(Negative control) 100 High calcium (1.2 mM) solution
(Positive control group) 210 (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 219

As shown in Table 1, when (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol was treated, the effect of promoting differentiation of keratinocytes was excellent I could confirm.

[Test Example 2] Measurement of skin barrier function recovery effect

In order to determine the effect of (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol on recovery of damaged skin barrier function due to skin damage, Experiments were performed. Ten adult male and female adult rats were treated for 7 days while applying two groups of Formulation Example 1 and Comparative Formulation Example 1, each of which had damage to the skin barrier using a tape stripping method, The recovery rate of TWEL was measured and compared with Vapometer (Delfin, Finland) once a day. Wherein Formulation Example 1 is a composition containing (2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol and Comparative Formulation Example 1 is a composition containing vehicle. The experimental results are shown in Table 3 below. The results in Table 3 were compared before treatment before barrier damage and after treatment before barrier damage on the basis of 100%.

Ingredients (% by weight) Formulation Example 1 Comparative Formulation Example 1 Purified water 69 70 Propylene glycol 30 30 (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol One -

Test group TWEL Change (%) Before processing 1 day 2 days 3 days 4 days 5 days 6 days Formulation Example 1 100 124 119 112 111 108 105 Comparative Formulation Example 1 100 121 112 98 70 62 43

As can be seen from Table 3, when (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol was treated, transdermal water loss was rapidly And the barrier damage is recovered.

[Test Example 3] Promotion of collagen biosynthesis

The effect of promoting collagen biosynthesis of (2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol according to the present invention was measured in comparison with TGF-β. First, fibroblast (cell line: KF-4109; available from Klebosha) was seeded on a 24-well plate at 10 ⁵ per well and cultured until it grew to about 90%. (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-leucine in Reference Example 1 dissolved in serum-free medium after incubation with serum-free DMEM medium for 24 hours. Glycerol and TGF-? Were treated at 10 ng / ml each, and CO ₂ And incubated in an incubator for 24 hours. The supernatant was removed and the procolagen (I) ELISA kit (procollagen type (I)) was used to determine whether procollagen was increased or decreased. The results are shown in Table 4, and the combined performance of the collagen was set to 100 in the non-treatment group.

Test substance Collagen Total Performance (%) Untreated group 100 TGF-beta 183.5 (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 172.7

In the results of the above Table 4, (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol used in the present invention exhibits a high level of excellent collagen- .

This suggests that a composition containing (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol according to the present invention is useful for skin regeneration.

[Referential Example 2] Formulation Example 2 and Comparative Formulation Example 2

Nutritive creams were prepared according to the composition of Table 5 below (unit: wt%).

Compounding ingredient Formulation Example 2 Comparative Formulation Example 2 Purified water To 100 To 100 (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 0.1 - Vegetable hydrogenated oil 1.50 1.50 Stearic acid 0.60 0.60 Glycerol stearate 1.00 1.00 Stearyl alcohol 2.00 2.00 Polyglyceryl-10pentastearate and behenyl alcohol and sodium stearoyl lactylate 1.00 1.00 Arachidyl behenyl alcohol and arachidyl glucoside 1.00 1.00 Cetylaryl Alcohol and Cetearyl Glucoside 2.00 2.00 PEG-100 Stearate & Glycerololate & Propylene Glycol 1.50 1.50 Caprylic / carboxy triglyceride 11.00 11.00 Cyclomedicone 6.00 6.00 Preservative, incense Suitable amount Suitable amount Triethanolamine 0.1 0.1

[Test Example 3] Measurement of skin moisturizing effect

(2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol on the skin moisturizing effect, the above Formulation Example 2 and Comparative Formulation Example 2 And evaluated as follows.

Twenty adult males and females in the 40s and 50s classified as dry skin were divided into two groups of 10 persons each for Formulation Example 2 and Comparative Formulation Example 2, and the nutritional cream was applied twice daily for 4 weeks to the face. (24 ° C, relative humidity 40%) after 1 week, 2 weeks, and 4 weeks after application, and after 2 weeks (total 6 weeks) (Corneometer CM825, C + K Electronic Co., Germany). The results are shown in Table 6 below. The results in Table 6 are based on the skin moisture meter measured immediately before the start of the test, and the increase in the measured value after treatment for a certain period is expressed as a percentage.

Test group Moisture growth rate (%) 1 week Two weeks 4 weeks 6 weeks Formulation Example 2 32 35 34 32 Comparative Formulation Example 2 30 32 32 15

The results of Table 6 show that when Comparative Formulation Example 2 is applied, the moisture increase rate is about 30% until 4 weeks of application, but the amount of skin moisture decreases sharply after stopping application, ) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol was applied, the skin moisture increase rate of at least 30% Can be confirmed. Thus, it can be seen that the composition of the present invention containing (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol has excellent skin moisturizing effect.

[Test Example 4] Confirmation of skin wrinkle improving effect

Formulation Example 2 and Comparative Formulation Example 2 were used to confirm the wrinkle-reducing effect of the composition of the present invention in humans.

In order to confirm the wrinkle-improving effect of Formulation Example 2 and Comparative Formulation Example 2, the following evaluation was made. Twenty healthy women in their 40s were divided into two groups of 10 people each for Formulation Example 2 and Comparative Formulation Example 2, and the nutritional cream was applied once a day for 12 weeks to the face, The state of the wrinkles was measured with a visiometer (SV600, Courage + Khazaka electronic GmbH, Germany) and the images were analyzed. The results are shown in Table 7 below. The values in Table 7 below are the average values obtained by subtracting the pre-application parameter values from the respective parameter values after 12 weeks of application.

After 8 weeks of use
Clinical outcome R1 R2 R3 R4 R5 Formulation Example 2 0.19 0.18 0.14 0.02 0.02 Comparative Formulation Example 2 0.27 0.26 0.21 0.03 0.03

R1: Difference between the maximum value and the minimum value of the wrinkle contour line

R2: The wrinkle contour line is arbitrarily divided into 5 squares, and the average of R1 values

R3: the highest value of R1 divided by 5

R4: average value obtained by subtracting the value of each apex and valley from the baseline of the wrinkle contour line

R5: Difference between the baseline of the wrinkle contour line minus each wrinkle contour

As shown in Table 7, it was found that the external preparation composition of Formulation Example 2 had an excellent effect of improving skin wrinkles.

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the pharmaceutical composition and the cosmetic composition can be applied to various formulations, and the present invention is not limited thereto but is specifically described.

[Formulation Example 1] Lotion

Lotions are prepared according to a conventional method with the composition shown in Table 8 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonyl phenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 2] Nourishing cream

Nutrition cream is prepared according to a conventional method with the composition shown in Table 9 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG 60 hardened castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / caproic triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 3] Massage cream

A massage cream is prepared according to a conventional method with the composition shown in Table 10 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 1.0 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 4] Pack

A pack is prepared according to a conventional method with the composition shown in Table 11 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonyl phenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 5] Gel

A gel is prepared according to a conventional method with the composition shown in Table 12 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 0.5 Ethylenediamine sodium acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 6] Ointment

Ointment was prepared by a conventional method with the composition shown in Table 13 below.

Content (% by weight) (2S) -1-O-linoleoyl-3-O- beta -D-galactopyranosyl-sn-glycerol 0.1 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Wax 4.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 7] Soft capsule

(2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol, 0.0025 g of vitamin C, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellowpearl and 6 mg of lecithin And 400 mg / capsule was filled according to a conventional method to prepare a soft capsule.

[Formulation Example 8] Tablets

Galactopyranosyl-sn-glycerol, 0.0025 g of vitamin C, 100 mg of glucose, 96 mg of starch, and 4 mg of magnesium stearate were mixed and mixed with 30 g of 30 (2S) -1-O-linoleoyl- % Ethanol was added thereto to form granules. The granules were then dried at 60 ° C and tableted using a tablet machine.

[Formulation Example 9]

Galactopyranosyl-sn-glycerol, 150 mg of vitamin C, 100 mg of glucose, and 600 mg of starch were mixed and 100 mg of 30% ethanol was added To form granules, followed by drying at 60 DEG C to form granules, which were then filled in a capsule. The final weight of the contents was 1 g.

[Formulation Example 10]

0.005 g of vitamin C, 10 g of glucose, 2 g of citric acid and 187.8 g of purified water were mixed and placed in a bottle. Respectively. The final volume of the contents was adjusted to 200 ml.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

(2S) -1-O-linoleoyl-3-O-? -D-galactopyranosyl-sn-glycerol represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

The composition according to claim 1, wherein the active ingredient is contained in an amount of 0.001 to 50% by weight based on the total weight of the composition. The composition of claim 1, wherein the composition is for enhancing skin barrier function. The composition of claim 1, wherein the composition is for inducing differentiation of dermal keratinocytes. The composition of claim 1, wherein the composition is for skin regeneration. The composition of claim 1, wherein the composition is a cosmetic composition.